Whose burden, whose benefit? Revisiting ethical trade-offs in the WHO guidelines on scaling up mass azithromycin administration.

New evidence suggests that mass drug administration of azithromycin (MDAA) can significantly reduce childhood mortality in high-burden, low-resource settings, yet the World Health Organization's (WHO) 2020 guidelines take a cautious approach due to concerns about antimicrobial resistance (AMR)....

全面介紹

書目詳細資料

發表在:	PLoS Medicine
Main Authors:	Maple Goh, A M Viens, Safura Abdool Karim, Aaron S Kesselheim, Kevin Outterson
格式:	Article
語言:	英语
出版:	Public Library of Science (PLoS) 2025-09-01
在線閱讀:	https://doi.org/10.1371/journal.pmed.1004736